WHO grants emergency use listing to Bharat Biotech's Covaxin

The global body's Technical Advisory Group has determined that Covaxin meets WHO standards for protection against COVID-19, the benefit of the vaccine far outweighs risks and the vaccine can be used, WHO said.

Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.

The World Health Organisation (WHO) on Wednesday granted emergency use listing (EUL) to Bharat Biotech's COVID-19 vaccine Covaxin.

The global body's Technical Advisory Group, made up of regulatory experts from around the world, has determined that Covaxin meets WHO standards for protection against COVID-19, the benefit of the vaccine far outweighs risks and the vaccine can be used, WHO said in a tweet.

🆕 WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. pic.twitter.com/dp2A1knGtT
— World Health Organization (WHO) (@WHO) November 3, 2021

(More details to follow)

TAGS:

WHO grants emergency use listing to Bharat Biotech's Covaxin

The global body's Technical Advisory Group has determined that Covaxin meets WHO standards for protection against COVID-19, the benefit of the vaccine far outweighs risks and the vaccine can be used, WHO said.

Videos